Testing a new drug called NRG-103 in people whose high-grade glioma has come back or is growing
Official title: A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing a new drug, NRG-103, in people whose high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has returned or is getting worse.
Read our full plain-language summary
What the trial team says
The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.
Key facts
- Registry number
- NCT07710690
- Stage of testing
- Phase 1
- Conditions studied
- HGG, High Grade Glioma (III or IV), High Grade Glioma
Where it is running
This trial lists 3 sites.
-
China
- Huashan Hospital Affiliated with Fudan University (Shanghai)
- Zhongnan Hospital of Wuhan University (Wuhan)
- The Second Affiliated Hospital of Air Force Medical University (Xi'an)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.